Abstract: An assay mixture includes a hydrogel of a shear-thinning ?-hairpin peptide, a plurality of cells, and one or more predetermined compounds being investigated for ability to affect the growth, viability, reproduction characteristics, or activity of the cells. A high throughput screening device includes a plurality of sample wells adapted for high throughput screening, wherein each well contains the assay mixture. A method of using the high throughput screening device includes a) depositing in each of the wells a ?-hairpin hydrogel including the cells; depositing in at least some of the wells one or more of the compounds, either along with the ?-hairpin hydrogel or separately; and c) measuring the growth, viability, reproduction characteristics, or activity of the cells in each of the plurality of wells.

Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.

Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.

Abstract: Methods are provided for increasing utrophin promoter activity, utrophin expression or utrophin activity, and treating or reducing the symptoms of muscular dystrophy by administering to a subject in need thereof an effective amount of a composition comprising a utrophin promoter or activity upregulator. Muscular dystrophy includes but is not limited to Duchenne muscular dystrophy, Becker's muscular dystrophy, limb girdle muscular dystrophy, or a disease characterized by mutation or dysregulation of the dystrophin gene or an aberrant or dysfunctional dystrophin.

Abstract: Compounds of formula (I), including methods of making and methods of using are described in formula (I).

Abstract: Catalytic antibodies are disclosed. The catalytic antibodies are specific for prodrug compounds. The catalytic antibodies enhance cleavage of an active drug moiety from a prodrug residue, thereby activating the drug.

Abstract: Disclosed and claimed are prodrugs activated by catalytic proteins, such as enzymes and catalytic antibodies. The invention comprehends such prodrugs, as well as haptens, to elicit catalytic antibodies to activate the prodrugs. The prodrugs are useful as cytotoxic chemotherapeutic agents; e.g., as antitumor agents.

Abstract: Described and claimed are compounds of the formula 1

Abstract: Prodrugs that are activated by and conjugated to a catalytic antibody conjugated to a moiety that binds to a tumor cell population are provided.

Abstract: Described and claimed are compounds of formula (I) wherein Y is a polypeptide, R.sub.1 is bonded to the N-terminus of Y and is hydrogen or a branched or linear, substituted or unsubstituted, C.sub.1-21 alkyl, alkene, or alkyne group, R.sub.2 is a side chain of a naturally occurring amino acid, and X is (a), (b), (c). Such compounds are useful as haptens and immunogens for the elicitation of antibodies which catalytically enhance the rate of formation or hydrolysis of primary amide bonds. Also described and claimed are methods employing the compounds and antibodies.

Abstract: A method of separating a pair of stereoisomers, and especially enantiomers, using monoclonal receptor molecules containing an antibody combining site that binds to substantially only one of that pair of stereoisomers is disclosed.

Abstract: A phosphorus-containing analog-ligand having a stereoconfiguration that substantially corresponds to the stereoconfiguration of an amide- or ester-forming transition state is used to induce production of receptor molecules whose antibody combining sites have stereospecific amide or ester synthase catalytic activity when reacted with a ligand containing (i) a carbonyl carbon atom and (ii) an amine or alcohol group that are structurally capable of forming a preselected stereoisomer of a carboxylic amide or ester.

Abstract: A phosphorous-containing analog-ligand having a conformation that substantially corresponds to the conformation of an amide- or ester-forming transition state is used to induce production of receptor molecules whose antibody combining sites have amide or ester synthase catalytic activity when reacted with a ligand containing (i) a carbonyl carbon atom and (ii) an amine or alcohol group that are structurally capable of forming a preselected carboxylic amide or ester bond.